Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, B-Cell

ClinicalTrials.gov lists 3,085 trials for Lymphoma, B-Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 196.

MeSH D016393 Neoplasms Neoplasm C04 C15 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 902 Phase 1/2 Phase 1/2 421 Phase 2 Phase 2 1,006 Phase 2/3 Phase 2/3 30 Phase 3 Phase 3 235 Phase 4 Phase 4 26 Not applicable Not applicable 166 Observational Observational 287 Phase 1 Phase 1 902 Phase 1/2 Phase 1/2 421 Phase 2 Phase 2 1,006 Phase 2/3 Phase 2/3 30 Phase 3 Phase 3 235 Phase 4 Phase 4 26 Not applicable Not applicable 166 Observational Observational 287

Trials per phase (log scale)

2 more sections with rows

771 of the 3,085 trials are tagged with Lymphoma, B-Cell itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, B-Cell report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, B-Cell trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 179

1990: 5 trials (Not applicable 1, Phase 2 3, Phase 1 1) 1991: 3 trials (Phase 2 2, Phase 1 1) 1992: 9 trials (Observational 2, Phase 3 1, Phase 2 5, Phase 1 1) 1993: 6 trials (Observational 1, Phase 3 2, Phase 2 3) 1994: 8 trials (Phase 3 3, Phase 2 3, Phase 1 2) 1995: 14 trials (Phase 3 4, Phase 2 6, Phase 1/2 1, Phase 1 3) 1996: 19 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 7, Phase 1 6) 1997: 43 trials (Observational 3, Not applicable 2, Phase 3 9, Phase 2/3 1, Phase 2 14, Phase 1/2 3, Phase 1 11) 1998: 45 trials (Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 22, Phase 1/2 3, Phase 1 14) 1999: 62 trials (Observational 1, Not applicable 4, Phase 3 8, Phase 2/3 1, Phase 2 18, Phase 1/2 6, Phase 1 24) 2000: 67 trials (Observational 3, Not applicable 4, Phase 3 6, Phase 2 32, Phase 1/2 6, Phase 1 16) 2001: 42 trials (Not applicable 5, Phase 3 9, Phase 2 11, Phase 1/2 3, Phase 1 14) 2002: 54 trials (Observational 2, Not applicable 5, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 21, Phase 1/2 3, Phase 1 17) 2003: 65 trials (Observational 1, Not applicable 6, Phase 3 11, Phase 2/3 1, Phase 2 27, Phase 1/2 7, Phase 1 12) 2004: 74 trials (Observational 2, Not applicable 7, Phase 3 4, Phase 2 35, Phase 1/2 6, Phase 1 20) 2005: 89 trials (Observational 7, Not applicable 6, Phase 3 6, Phase 2 42, Phase 1/2 12, Phase 1 16) 2006: 78 trials (Observational 6, Not applicable 3, Phase 4 1, Phase 3 9, Phase 2 32, Phase 1/2 10, Phase 1 17) 2007: 89 trials (Other 1, Observational 5, Not applicable 7, Phase 3 10, Phase 2 36, Phase 1/2 4, Phase 1 26) 2008: 78 trials (Observational 12, Not applicable 2, Phase 3 6, Phase 2 26, Phase 1/2 15, Phase 1 17) 2009: 68 trials (Other 1, Observational 10, Not applicable 4, Phase 3 4, Phase 2 26, Phase 1/2 6, Phase 1 17) 2010: 79 trials (Observational 7, Not applicable 8, Phase 3 3, Phase 2/3 2, Phase 2 29, Phase 1/2 13, Phase 1 17) 2011: 73 trials (Observational 4, Not applicable 2, Phase 3 7, Phase 2 33, Phase 1/2 11, Phase 1 16) 2012: 65 trials (Observational 4, Not applicable 5, Phase 4 1, Phase 3 5, Phase 2 22, Phase 1/2 10, Phase 1 18) 2013: 76 trials (Observational 7, Not applicable 3, Phase 3 6, Phase 2/3 1, Phase 2 22, Phase 1/2 12, Phase 1 25) 2014: 71 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2 12, Phase 1/2 18, Phase 1 28) 2015: 85 trials (Observational 6, Not applicable 2, Phase 4 1, Phase 3 10, Phase 2 31, Phase 1/2 14, Phase 1 21) 2016: 128 trials (Observational 14, Not applicable 5, Phase 4 4, Phase 3 5, Phase 2/3 5, Phase 2 35, Phase 1/2 26, Phase 1 34) 2017: 138 trials (Observational 9, Not applicable 3, Phase 4 3, Phase 3 9, Phase 2/3 2, Phase 2 43, Phase 1/2 27, Phase 1 42) 2018: 120 trials (Observational 8, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2 38, Phase 1/2 17, Phase 1 48) 2019: 141 trials (Observational 6, Not applicable 5, Phase 4 1, Phase 3 9, Phase 2/3 1, Phase 2 37, Phase 1/2 16, Phase 1 66) 2020: 149 trials (Observational 23, Not applicable 6, Phase 3 9, Phase 2/3 1, Phase 2 34, Phase 1/2 24, Phase 1 52) 2021: 164 trials (Observational 23, Not applicable 3, Phase 4 1, Phase 3 20, Phase 2/3 1, Phase 2 42, Phase 1/2 23, Phase 1 51) 2022: 167 trials (Observational 19, Not applicable 11, Phase 4 1, Phase 3 9, Phase 2/3 2, Phase 2 48, Phase 1/2 29, Phase 1 48) 2023: 166 trials (Observational 26, Not applicable 10, Phase 4 4, Phase 3 8, Phase 2 40, Phase 1/2 24, Phase 1 54) 2024: 166 trials (Observational 21, Not applicable 17, Phase 4 1, Phase 3 7, Phase 2/3 3, Phase 2 53, Phase 1/2 19, Phase 1 45) 2025: 179 trials (Observational 24, Not applicable 9, Phase 4 3, Phase 3 7, Phase 2/3 4, Phase 2 62, Phase 1/2 23, Phase 1 47)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 160
2025 179
2024 166
2023 166
2022 167
2021 164
2020 149
2019 141
2018 120
2017 138

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 180 trials starting in 2026 and about 180 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 467 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 1,721 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, B-Cell trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 902
Phase 1/2 421
Phase 2 1,006
Phase 2/3 30
Phase 3 235
Phase 4 26
Not applicable 166
Observational 287
Expanded access 11
Unknown 1

How many Lymphoma, B-Cell trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 139
Recruiting 480
Enrolling by invitation 8
Active, not recruiting 236
Available 4

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, B-Cell trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 196
Novartis Pharmaceuticals 35
Hoffmann-La Roche 30
Children's Oncology Group 26

Which drugs are being tested for Lymphoma, B-Cell? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 559
Cytoxan 509
Prednisone 225

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Vincristina 237
SQ Fludarabine 228
Doxorubicine 217
Etoposid 200
Cytarabine IT 136

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, B-Cell trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 2,305 207
Neutrophil count decreased 1,383 85
Pneumonia 1,243 180
Platelet count decreased 1,078 90
Pyrexia 881 129

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, B-Cell? (502)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 2025 Yes
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood advances 2025 Yes
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet (London, England) 2025 Yes
Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022. Blood advances 2025 Yes
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma. Blood advances 2025 Yes

Showing 5 of 502 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages